Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014

Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014

Summary

GBI Research, the leading business intelligence provider, has released its latest report, “Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014”. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the major musculoskeletal disorders, including rheumatoid arthritis, osteoporosis, osteoarthritis, low back pain and muscular dystrophy. The report also provides the share of generics in global market as well as for each indication. It also provides the treatment flow algorithm for each of the five indications. The report examines the global musculoskeletal disorders treatment usage patterns. In addition, our research details the geographical distribution of musculoskeletal disorders markets across the US, the top five countries of Europe, and Japan.The report also includes insight into the musculoskeletal disorders R&D product pipeline and explores the competitive landscape, including major players in the musculoskeletal disorders therapeutics market. Finally, the report includes analysis of Mergers and Acquisitions (M&As) and licensing agreements that took place in the market in recent years.

GBI Research’s analysis shows that the overall global musculoskeletal disorders therapeutics market for the five indications (which includes rheumatoid arthritis, osteoporosis, osteoarthritis, low back pain and muscular dystrophy) was valued at $33.4 billion in 2010, indicating a CAGR of 5.7% over the previous year. GBI Research forecasts the market to grow at a CAGR of 7.3% between 2010 and 2017, to record a sales value of $54.8 billion by 2017. The growth in major markets such as the US and the top five countries in the EU and Japan were driven by new developments that created more options in the treatment of rheumatoid arthritis, osteoporosis, osteoarthritis, muscular dystrophy and low back pain. The global musculoskeletal disorders market is expected to witness a series of patent expiries between 2010 and 2017, which includes some top selling drugs such as Cymbalta (duloxetine HCl) and Celebrex (celecoxib). The future of the market is based on the success of the drugs in the pipeline; while the current musculoskeletal disorders market pipeline holds strong prospects for growth in the future, these factors will not be able to completely offset the challenge from generic competition. Muscular dystrophy is one of the most commonly recognized musculoskeletal disorders, but there are no approved therapeutic options available for this disease. For this reason, the generic share continues to rise in the market.

Scope

- Data and analysis on the musculoskeletal disorders therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the market from 2002 to 2010, with forecasts to 2017 for the three indications – rheumatoid arthritis, osteoporosis, osteoarthritis, low back pain and muscular dystrophy.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Share of the generics in the global musculoskeletal disorders therapeutics market and for the market of each indication that is covered in the report.
- Key drivers and restraints that have had a significant impact on the market.
- The competitive landscape of the market, including top companies benchmarking. The key companies studied in this report are Pfizer Inc., Eli Lilly, Johnson & Johnson, Amgen Inc. and Abbott Laboratories.
- Key M&A activities and Licensing Agreements that took place in 2009 and 2011 in the musculoskeletal disorders therapeutics market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Global Therapy Industry

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 8
2 Musculoskeletal Disorders Therapeutics Market to 2017 -Introduction 11
2.1 GBI Research Report Guidance 11
3 Musculoskeletal Disorders Therapeutics Market to 2017 - Market Overview 13
3.1 Introduction 13
3.1.1 Revenue 13
3.1.2 Annual Cost of Treatment 14
3.1.3 Treatment Usage Pattern 15
4 Musculoskeletal Disorders Therapeutics Market to 2017 -Geographical Landscape 20
4.1 Revenue Analysis by Geography 20
4.2 The US 22
4.2.1 Revenue 22
4.2.2 Annual Cost of Treatment 23
4.2.3 Treatment Usage Patterns 24
4.3 Top Five Countries of Europe 27
4.3.1 Revenue 27
4.3.2 Annual Cost of Treatment 30
4.3.3 Treatment Usage Patterns 31
4.4 Japan 33
4.4.1 Revenue 33
4.4.2 Annual Cost of Treatment 34
4.4.3 Treatment Usage Patterns 35
5 Musculoskeletal Disorders Therapeutics Market to 2017 - Therapeutic Landscape 37
5.1 Rheumatoid Arthritis Therapeutics Market 37
5.1.1 Introduction 37
5.1.2 Revenue 37
5.1.3 Annual Cost of Treatment 41
5.1.4 Treatment Usage Pattern 42
5.1.5 Treatment Flow Algorithm 48
5.1.6 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market 48
5.2 Osteoporosis Therapeutics 50
5.2.1 Introduction 50
5.2.2 Revenue 50
5.2.3 Annual Cost of Treatment 54
5.2.4 Treatment Usage Patterns 55
5.2.5 Treatment Flow Algorithm 60
5.2.6 Drivers and Barriers for Osteoporosis Therapeutics Market 60
5.3 Osteoarthritis Therapeutics 62
5.3.1 Introduction 62
5.3.2 Revenue 62
5.3.3 Annual Cost of Treatment 66
5.3.4 Treatment Usage Patterns 67
5.3.5 Treatment Flow Algorithm 72
5.3.6 Drivers and Barriers for Osteoarthritis Therapeutics Market 72
5.4 Low Back Pain Therapeutics 74
5.4.1 Introduction 74
5.4.2 Revenue 74
5.4.3 Annual Cost of Treatment 79
5.4.4 Treatment Usage Patterns 80
5.4.5 Treatment Flow Algorithm 85
5.4.6 Drivers and Barriers for Low Back Pain Therapeutics Market 86
5.5 Muscular Dystrophy Therapeutics 87
5.5.1 Introduction 87
5.5.2 Revenue 87
5.5.3 Annual Cost of Treatment 90
5.5.4 Treatment Usage Patterns 91
5.5.5 Treatment Flow Algorithm 96
5.5.6 Drivers and Barriers for Muscular Dystrophy Therapeutics Market 96
6 Musculoskeletal Disorders Therapeutics Market to 2017 - Pipeline Analysis 98
6.1 Introduction 98
6.2 Musculoskeletal Disorders Therapeutics Market – Pipeline Assessment by Clinical Phase of Development 100
6.2.1 NDA Filed Molecules 100
6.2.2 Phase III 102
6.2.3 Phase II 113
6.2.4 Phase I 117
6.2.5 Preclinical Phase 119
6.2.6 Discovery Phase 123
6.3 Profiles of Promising Molecules in the Musculoskeletal Disorders Therapeutics Market 125
6.3.1 YM529 (minodronate) 125
6.3.2 EX101 (alendronate) 125
6.3.3 MAbThera (rituximab) 126
6.3.4 Actemra (tocilizumab) 127
6.3.5 Simponi 128
6.3.6 Naproxcinod 128
6.3.7 Iguratimod 129
7 Musculoskeletal Disorders Therapeutics Market to 2017 - Competitive Profiling 130
7.1 Competitive Profiling 130
7.1.1 Abbott Laboratories 130
7.1.2 Johnson & Johnson 131
7.1.3 Amgen Inc. 132
7.1.4 Pfizer Inc 133
7.1.5 Eli Lilly and Company 134
8 Musculoskeletal Disorders Therapeutics Market to 2017 - Strategic Consolidations 136
8.1 Mergers and Acquisitions 136
8.1.1 Segmentation by Deal Value 139
8.1.2 Segmentation by Geography 142
8.2 Co-development Deals 143
8.2.1 Summary of Co-development Deals 145
8.3 Licensing Deals 147
8.3.1 Summary of Licensing Deals 150
9 Musculoskeletal Disorders Therapeutics Market to 2017 - Appendix 153
9.1 Market Definitions 153
9.2 Abbreviations 153
9.3 Research Methodology 154
9.3.1 Coverage 154
9.3.2 Secondary Research 154
9.3.3 Primary Research 155
9.4 Therapeutic Landscape 155
9.4.1 Epidemiology-based Forecasting 156
9.4.2 Market Size by Geography 157
9.5 Geographical Landscape 158
9.6 Pipeline Analysis 158
9.7 Competitive Landscape 158
9.7.1 Expert Panel Validation 158
9.8 Contact Us 158
9.9 Disclaimer 159
9.10 Sources 159

1.1 List of Tables
Table 1: Musculoskeletal Disorders Therapeutics Market, Global, Revenue ($bn), 2002-2010 13
Table 2: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 13
Table 3: Musculoskeletal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 14
Table 4: Musculoskeletal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 14
Table 5: Musculoskeletal Disorders Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010 15
Table 6: Musculoskeletal Disorders Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2017 16
Table 7: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 20
Table 8: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 21
Table 9: Musculoskeletal Disorders Therapeutics Market, The US, Revenue ($bn), 2002-2010 22
Table 10: Musculoskeletal Disorders Therapeutics Market, The US, Revenue Forecasts ($bn), 2010-2017 22
Table 11: Musculoskeletal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2010 23
Table 12: Musculoskeletal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2010-2017 23
Table 13: Musculoskeletal Disorders Therapeutics Market, The US, Treatment Usage Patterns (Millions), 2002-2010 24
Table 14: Musculoskeletal Disorders Therapeutics Market, The US, Treatment Usage Patterns (Millions), 2010-2017 25
Table 15: Musculoskeletal Disorders Therapeutics Market , Top Five Countries of Europe, Revenue ($bn), 2002-2010 27
Table 16: Musculoskeletal Disorders Therapeutics Market , Top Five Countries of Europe, Revenue Forecasts ($bn), 2010-2017 27
Table 17: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue by Country ($bn), 2002-2010 28
Table 18: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue by Country ($bn), 2010-2017 29
Table 19: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010 30
Table 20: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017 30
Table 21: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (Millions), 2002-2010 31
Table 22: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (Millions), 2010-2017 32
Table 23: Musculoskeletal Disorders Therapeutics Market, Japan, Revenue ($bn), 2002-2010 33
Table 24: Musculoskeletal Disorders Therapeutics Market, Japan, Revenue Forecasts ($bn), 2010-2017 33
Table 25: Musculoskeletal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2010 34
Table 26: Musculoskeletal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2017 34
Table 27: Musculoskeletal Disorders Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2002-2010 35
Table 28: Musculoskeletal Disorders Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010-2017 36
Table 29: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2002-2010 38
Table 30: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017 38
Table 31: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 39
Table 32: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 39
Table 33: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 41
Table 34: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment($), 2010-2017 42
Table 35: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010 43
Table 36: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2017 43
Table 37: Osteoporosis Therapeutics Market, Global, Revenue ($bn), 2002-2010 50
Table 38: Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 50
Table 39: Osteoporosis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 51
Table 40: Osteoporosis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 52
Table 41: Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 54
Table 42: Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 54
Table 43: Osteoporosis Therapeutics Market, Global, Treatment Usage Pattern (Millions), 2002-2010 55
Table 44: Osteoporosis Therapeutics Market, Global, Treatment Usage Pattern (Millions), 2010-2017 56
Table 45: Osteoarthritis Therapeutics Market, Global, Revenue ($bn), 2002-2010 63
Table 46: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 63
Table 47: Osteoarthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 64
Table 48: Osteoarthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 64
Table 49: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 66
Table 50: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 66
Table 51: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2002-2010 67
Table 52: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2010-2017 68
Table 53: Low Back Pain Therapeutics Market, Global, Revenue ($bn), 2002-2010 74
Table 54: Low Back Pain Therapeutics Market, Global, Revenue Forecasts ($bn), 2010-2017 75
Table 55: Low Back Pain Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 76
Table 56: Low Back Pain Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 77
Table 57: Low Back Pain Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 79
Table 58: Low Back Pain Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 79
Table 59: Low Back Pain Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2002-2010 80
Table 60: Low Back Pain Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2010-2017 81
Table 61: Muscular Dystrophy Therapeutics Market, Global, Revenue ($m), 2002-2010 87
Table 62: Muscular Dystrophy Therapeutics Market, Global, Revenue Forecasts ($m), 2010-2017 87
Table 63: Muscular Dystrophy Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010 89
Table 64: Muscular Dystrophy Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017 89
Table 65: Muscular Dystrophy Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 90
Table 66: Muscular Dystrophy Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 90
Table 67: Muscular Dystrophy Therapeutics Market, Global, Treatment Usage Patterns (000’s), 2002-2010 91
Table 68: Muscular Dystrophy Therapeutics Market, Global, Treatment Usage Patterns (000’s), 2010-2017 92
Table 69: Musculoskeletal Disorders Therapeutics Market, Global, Pipeline Analysis, NDA Filed Molecules, July 2011 100
Table 70: Musculoskeletal Disorders Therapeutics Market, Global, Pipeline Analysis, Phase III, July 2011 102
Table 71: Musculoskeletal Disorders Therapeutics Market, Global, Pipeline Analysis, Phase II, July 2011 113
Table 72: Musculoskeletal Disorders Therapeutics Market, Global, Pipeline Analysis, Phase I, July 2011 117
Table 73: Musculoskeletal Disorders Therapeutics Market, Global, Pipeline Analysis, Preclinical Phase, July 2011 119
Table 74: Musculoskeletal Disorders Therapeutics Market, Global, Pipeline Analysis, Discovery Phase, July 2011 123
Table 75: Musculoskeletal Disorders Therapeutics Market, Global, M&A, 2009-2011 137
Table 76: Musculoskeletal Disorders Therapeutics Market, M&A Deals, By Value ($m) 2009-2011 140
Table 77: Musculoskeletal Disorders Therapeutics Market, Co-development, By Geography, 2009-2011 143
Table 78: Musculoskeletal Disorders Therapeutics Market, Licensing Deals, By Geography, 2009-2011 147

1.2 List of Figures
Figure 1: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 13
Figure 2: Musculoskeletal Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 14
Figure 3: Musculoskeletal Disorders Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2017 15
Figure 4: Musculoskeletal Disorders Therapeutics Market, Global, Diseased Population (millions), 2002-2017 16
Figure 5: Musculoskeletal Disorders Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2017 17
Figure 6: Musculoskeletal Disorders Therapeutics Market, Global, Diagnosed Population (millions), 2002-2017 18
Figure 7: Musculoskeletal Disorders Therapeutics Market, Global, Prescription Population (millions), 2002-2017 19
Figure 8: Musculoskeletal Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017 20
Figure 9: Musculoskeletal Disorders Therapeutics Market, The US, Revenue Forecasts ($bn), 2002-2017 22
Figure 10: Musculoskeletal Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2017 23
Figure 11: Musculoskeletal Disorders Therapeutics Market, The US, Treatment Usage Patterns (Millions), 2002-2017 24
Figure 12: Musculoskeletal Disorders Therapeutics Market , Top Five Countries of Europe, Revenue Forecasts ($bn), 2002-2017 27
Figure 13: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Revenue by Country ($bn), 2002-2017 28
Figure 14: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 30
Figure 15: Musculoskeletal Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (Millions), 2002-2017 31
Figure 16: Musculoskeletal Disorders Therapeutics Market, Japan, Revenue ($bn), 2002-2017 33
Figure 17: Musculoskeletal Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2017 34
Figure 18: Musculoskeletal Disorders Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2002-2017 35
Figure 19: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 37
Figure 20: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017 38
Figure 21: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Segmentation 40
Figure 22: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 41
Figure 23: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2017 42
Figure 24: Rheumatoid Arthritis Therapeutics Market, Global, Diseased Population (Millions), 2002-2017 44
Figure 25: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Seeking Population (Millions), 2002-2017 45
Figure 26: Rheumatoid Arthritis Therapeutics Market, Global, Diagnosed Population (Millions), 2002-2017 46
Figure 27: Rheumatoid Arthritis Therapeutics Market , Global, Prescription Population (Millions), 2002-2017 47
Figure 28: Musculoskeletal Disorders Therapeutics Market, Global, Rheumatoid Arthritis Pain, Treatment Algorithm 48
Figure 29: Rheumatoid Arthritis, Market Drivers and Barriers, 2010-2017 49
Figure 30: Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 50
Figure 31: Osteoporosis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017 51
Figure 32: Osteoporosis Therapeutics Market, Global, Branded and Generics Share, 2010 & 2017 53
Figure 33: Osteoporosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 54
Figure 34: Osteoporosis Therapeutics Market, Global, Treatment Usage Pattern (Millions), 2002-2017 55
Figure 35: Osteoporosis Therapeutics Market, Global, Diseased Population (Millions), 2002-2017 56
Figure 36: Osteoporosis Therapeutics Market, Global, Treatment Seeking Population (Millions), 2002-2017 57
Figure 37: Osteoporosis Therapeutics Market, Global, Diagnosed Population (Millions), 2002-2017 58
Figure 38: Osteoporosis Therapeutics Market , Global, Prescription Population (Millions), 2002-2017 59
Figure 39: Musculoskeletal Disorders Therapeutics Market, Global, Osteoporosis, Treatment Algorithm 60
Figure 40: Osteoporosis, Market Drivers and Barriers, 2010-2017 61
Figure 41: Osteoarthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 62
Figure 42: Osteoarthritis Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017 63
Figure 43: Osteoarthritis Therapeutics Market, Global, Branded and Generics Share, 2010 & 2017 65
Figure 44: Osteoarthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 66
Figure 45: Osteoarthritis Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2002-2017 67
Figure 46: Osteoarthritis Therapeutics Market, Global, Diseased Population (Millions), 2002-2017 68
Figure 47: Osteoarthritis Therapeutics Market, Global, Treatment Seeking Population (Millions), 2002-2017 69
Figure 48: Osteoarthritis Therapeutics Market, Global, Diagnosed Population (Millions), 2002-2017 70
Figure 49: Osteoarthritis Therapeutics Market, Global, Prescription Population (Millions), 2002-2017 71
Figure 50: Musculoskeletal Disorders Therapeutics Market, Global, Osteoarthritis, Treatment Algorithm 72
Figure 51: Osteoarthritis, Market Drivers and Barriers, 2010-2017 73
Figure 52: Low Back Pain Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 74
Figure 53: Low Back Pain Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017 76
Figure 54: Low Back Pain Therapeutics Market, Global, Branded and Generics Share (%), 2010 & 2017 78
Figure 55: Low Back Pain Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 79
Figure 56: Low Back Pain Therapeutics Market, Global, Treatment Usage Patterns (Millions), 2002-2017 80
Figure 57: Low Back Pain Therapeutics Market, Global, Diseased Population (Millions), 2002-2017 81
Figure 58: Low Back Pain Therapeutics Market, Global, Treatment Seeking Population (Millions), 2002-2017 82
Figure 59: Low Back Pain Therapeutics Market, Global, Diagnosed Population (Millions), 2002-2017 83
Figure 60: Low Back Pain Therapeutics Market, Global, Prescription Population (Millions), 2002-2017 84
Figure 61: Musculoskeletal Disorders Therapeutics Market, Global, Low Back Pain, Treatment Algorithm 85
Figure 62: Low Back Pain, Market Drivers and Barriers, 2010-2017 86
Figure 63: Muscular Dystrophy Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 87
Figure 64: Muscular Dystrophy Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017 88
Figure 65: Muscular Dystrophy Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 90
Figure 66: Muscular Dystrophy Therapeutics Market, Global, Treatment Usage Patterns (000’s), 2002-2017 91
Figure 67: Muscular Dystrophy Therapeutics Market, Global, Diseased Population (000’s), 2002-2017 92
Figure 68: Muscular Dystrophy Therapeutics Market, Global, Treatment Seeking Population (000’s), 2002-2017 93
Figure 69: Muscular Dystrophy Therapeutics Market, Global, Diagnosed Population (000’s), 2002-2017 94
Figure 70: Muscular Dystrophy Therapeutics Market, Global, Prescription Population (000’s), 2002-2017 95
Figure 71: Musculoskeletal Disorders Therapeutics Market, Global, Muscular Dystrophy, Treatment Algorithm 96
Figure 72: Muscular Dystrophy, Market Drivers and Barriers, 2010-2017 97
Figure 73: Musculoskeletal Disorders Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011 98
Figure 74: Musculoskeletal Disorders Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 99
Figure 75: Musculoskeletal Disorders Therapeutics Market, Global, SWOT – Abbott Laboratories, 2010 130
Figure 76: Musculoskeletal Disorders Therapeutics Market, Global, SWOT – Johnson & Johnson, 2010 131
Figure 77: Musculoskeletal Disorders Therapeutics Market, Global, SWOT – Amgen Inc., 2010 132
Figure 78: Musculoskeletal Disorders Therapeutics Market, Global, SWOT – Pfizer, 2010 134
Figure 79: Musculoskeletal Disorders Therapeutics Market, Global, SWOT – Eli Lilly, 2010 135
Figure 80: Musculoskeletal Disorders Therapeutics Market, Global, Deals by Indications, 2009-2011 136
Figure 81: Musculoskeletal Disorders Therapeutics Market, M&A Deals, By Value ($m) 2009-2011 139
Figure 82: Musculoskeletal Disorders Therapeutics Market, M&A Deals, By Geography, 2009-2011 142
Figure 83: Musculoskeletal Disorders Therapeutics Market, Co-development, By Indications, 2009-2011 143
Figure 84: Musculoskeletal Disorders Therapeutics Market, Licensing Deals, By Geography, 2009-2011 150
Figure 85: GBI Research Market Forecasting Model 157

Companies mentioned

Abbott Laboratories
Johnson & Johnson
Amgen Inc.
Pfizer Inc
Eli Lilly and Company